Funding for this research was provided by:
PTC Therapeutics International Ltd
Received: 3 October 2021
Accepted: 27 February 2022
First Online: 21 March 2022
: This study was submitted for ethical review by the WIRB-Copernicus Group Independent Review Board and was granted an exemption (tracking number: #1-1327023-1). All participants provided informed consent before taking part.
: Participants provided their consent for their data to be published in peer-reviewed academic journals before taking part in the study.
: Kate Williams, Hanna Skrobanski and Sarah Acaster are employees of Acaster Lloyd Consulting Ltd. Katharina Buesch is an employee of PTC Therapeutics.